ER, PR and HER2 testing in breast cancer

Han, Guangming

doi:10.1016/j.mpdhp.2014.10.002

Cited by 4 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that HER2 -negative tumors include low-grade carcinomas with ER-positive and infiltrative ductal or lobular histology. 24 Our findings were also found to support the literature.…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Evaluation of the Relationships between ER, PR, c-erbB2, Ki67, E-Cadherin Expressions, Nottingham Histological Grade and some Clinical Parameters in Breast Carcinomas

Çelik

Arıcı

2023

Online Türk Sağlık Bilimleri Dergisi

View full text Add to dashboard Cite

To Aim: In this study, it was aimed to evaluate the relationships between Estrogen (ER), Progesterone (PR), c-erbB2, Ki67, E-Cadherin expressions, Nottingham histological grade and some clinical parameters in breast carcinomas. Material and Methods: A total of 74 patients diagnosed with breast carcinoma in our pathology department between 2018-2019 were included in this study. Immunohistochemical preparations stained with ER, PR, c-erbB2, Ki67, E-Cadherin were evaluated and analyzed retrospectively. For ER and PR, ≥1% expression was considered positive staining, and

show abstract

Section: Discussionsupporting

confidence: 88%

“…False-negative results may cause patients to be deprived of treatment. 24 Our ER and PR expression rates were followed in line with the literature. In our study, HER2 score showed a statistically significant change according to ER status (p:0.010).…”

Section: Discussionmentioning

confidence: 78%

Evaluation of the Relationships between ER, PR, c-erbB2, Ki67, E-Cadherin Expressions, Nottingham Histological Grade and some Clinical Parameters in Breast Carcinomas

Çelik

Arıcı

2023

Online Türk Sağlık Bilimleri Dergisi

View full text Add to dashboard Cite

show abstract

“…According to the international practice, [ 16 ] ER and PR positivity were defined using the cut-off values of 1% and 10%. [ 5 ] Therefore, positive cells of ER or PR rate< 1% were considered as negative, marked as “0,” 1%–10% as low expression, marked as “1+,” > 10% were positive and marked as “2+.” Her-2 positive is expressed in cell membrane, and the results of Her-2 were calculated by the percentage of tumor cell membrane which showed a completely shading and tinting strength. [ 8 ] The negative staining results and the cells whose cell membrane were stained less than 10% of tumor cells were marked as “0”; “1+” was marked for the tumor cells >10% and <30% where the cell membrane staining intensity showed light and barely visible performance cells, and the cell membranes were partly stained.…”

Section: Methodsmentioning

confidence: 99%

“…As a sex hormone dependent organ, the cell proliferation and development of breast are controlled by estrogen and progesterone hormones. [ 5 ] Therefore, estrogen and progesterone are important endocrine factors that not only were involved in the normal development of breast, but also in the induction of breast cancer. Estrogen receptor (ER) and progesterone receptor (PR) play an important biological function role by specifically combining with estrogen and progesterone.…”

Section: Introductionmentioning

confidence: 99%

“…Higher positive expressions of ER and PR demonstrated breast cancer with a higher degree of differentiation, low malignant degree, and with better prognosis. [ 5 – 7 ] Human epidermal growth factor receptor 2 (Her-2) is one of the genetic markers that is commonly observed in breast cancer, which is positively correlated with the amplification and higher protein expression and in turn in the progression of breast cancer. [ 8 ] Her-2 is rarely expressed in normal tissues, and is expressed positively in poorly differentiated and invasive breast cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between the dynamic contrast-enhanced MRI features and prognostic factors in breast cancer

Tao

Bai

et al. 2018

Medicine

View full text Add to dashboard Cite

This study analyzed the correlation between the dynamic contrast-enhanced MRI (DCE-MRI) features with prognostic factors of breast cancer. Eighty-five breast cancer patients verified by pathology and immunohistochemistry underwent DCE-MRI examination. Spearman correlation analysis was used to analyze the DCE-MRI features [the strengthening types, shape, distribution, edge, internal reinforcement and the time-signal intensity curve (TIC) types] and the 4 immunohistochemical markers (ER, PR, Her-2, and Ki-67) by GraphPad InStat version 6.0 software. The enhanced morphology types, shapes, edge had significant correlation with the expression of ER (P = .001, P = .000, P = .001, respectively), PR (P = .045, P = .015, P = .000, respectively) and Ki-67 (P = .039, P = .000, P = .024, respectively), and no significant correlation with Her-2 expression (P = .906, P = .074, P = .679, respectively) was observed. There was significant correlation between internal enhancement patterns and Ki-67 expression (P = .004), and no significant correlation between internal enhancement patterns and the expression of ER, PR, and Her-2 (P = .208, P = .682, P = .437, respectively) was observed. TIC had significant correlation with ER, Ki-67 expressions (P = .022, P = .001, respectively), and no correlation with expressions of PR and Her-2 (P = .128, P = .391, respectively) was observed. The DCE-MRI features of breast cancer were well correlated with the expression of immunohistochemistry, and might also be helpful to evaluate the biological progress and prognosis.

show abstract

Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype

Chen

Zhang

et al. 2020

Clin Epigenet

View full text Add to dashboard Cite

Background: Breast cancer (BRCA) is a heterogeneous disease, characterized by different histopathological and clinical features and responses to various therapeutic measures. Despite the research progress of DNA methylation in classification and diagnosis of BRCA and the close relationship between DNA methylation and hormone receptor status, especially estrogen receptor (ER), the epigenetic mechanisms in various BRCA subtypes and the biomarkers associated with diagnostic characteristics of patients under specific hormone receptor status remain elusive. Results: In this study, we collected and analyzed methylation data from 785 invasive BRCA and 98 normal breast tissue samples from The Cancer Genome Atlas (TCGA) database. Consensus classification analysis revealed that ERpositive BRCA samples were constitutive of two distinct methylation subgroups; with the hypomethylated subgroup showing good survival probability. This finding was further supported by another cohort of ER-positive BRCA containing 30 subjects. Additionally, we identified 977 hypomethylated CpG loci showing significant associations with good survival probability in ER-positive BRCA. Genes with these loci were enriched in cancerrelated pathways (e.g., Wnt signaling pathway). Among them, the upregulated 47 genes were also in line with good survival probability of ER-positive BRCA, while they showed significantly negative correlations between their expression and methylation level of certain hypomethylated loci. Functional assay in numerous literatures provided further evidences supporting that some of the loci have close links with the modulation of tumor-suppressive mechanisms via regulation gene transcription (e.g., SFRP1 and WIF1). Conclusions: Our study identified a hypomethylated ER-positive BRCA subtype. Notably, this subgroup presented the best survival probability compared with the hypermethylated ER-positive and hypomethylated ER-negative BRCA subtypes. Specifically, we found that certain upregulated genes (e.g., SFRP1 and WIF1) have great potential to suppress the progression of ER-positive BRCA, concurrently exist negative correlations between their expression and methylation of corresponding hypomethylated CpG loci. Therefore, our study indicates that different epigenetic mechanisms likely exist in ER-positive BRCA and provides novel clinical biomarkers specific to ER-positive BRCA diagnosis and therapy.

show abstract

ER, PR and HER2 testing in breast cancer

Cited by 4 publications

References 25 publications

Evaluation of the Relationships between ER, PR, c-erbB2, Ki67, E-Cadherin Expressions, Nottingham Histological Grade and some Clinical Parameters in Breast Carcinomas

Evaluation of the Relationships between ER, PR, c-erbB2, Ki67, E-Cadherin Expressions, Nottingham Histological Grade and some Clinical Parameters in Breast Carcinomas

Correlation between the dynamic contrast-enhanced MRI features and prognostic factors in breast cancer

Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype

Contact Info

Product

Resources

About